Today's Date: September 23, 2021
Federal Title & Escrow Company Donates to Women's Organization Working to End Homelessness in Nation's Capital   •   Chicago Children's Museum Launches Construction Of Its Newest Exhibit, Moen Presents Water City   •   Strategic Objectives Co-Founders Awarded CPRS National's 2021 Entrepreneurial Leadership Award   •   HERO Beverage Co. Launches a Line of Coffee Honoring the Late Chris Kyle   •   Athletic Brewing, the Brewer Leading the Non-Alcoholic Craft Beer Movement, Takes Home Top Awards at Three Major Beer Competitio   •   PEWIN Announces 2021 Annual LP/GP Awards Recipients   •   Skechers Announces Updated Fireside Chat Time at the Morgan Stanley Virtual Global Sporting Goods Day   •   Virginia GrandDriver Goes Retro with New 80's-Themed Workout Series Aimed to Help Older Drivers Get Fit, Drive Safely, and Have   •   DKT International Publishes 2020 Contraceptive Social Marketing Statistics   •   Naples Soap Co. Signs Lease for a New Store Location in Kissimmee, Fla.   •   The Boston Globe To Launch "Black News Hour," Hosting Boston Mayoral Candidates For Debut Episode September 24th   •   Photographer Merik Goma To Begin Artist In Residence At The Amistad Center   •   National Park Foundation Board Directors Honor Latino Heritage by Helping to Preserve and Elevate Stories in National Parks   •   A New 3D Kirby Game, First Look at Bayonetta 3 and a Massive Expansion for MONSTER HUNTER RISE Highlight the Latest Nintendo Dir   •   At-Risk Shelter Dogs Given Another Chance at Life with Veterans and Inmates through Marley's Mutts ® Pawsitive Change Progra   •   SICO Paint by PPG Unveils 2022 Colour of the Year: Cool Current   •   DeAndre Hopkins, NFL FLAG, Arizona Cardinals Debut DeAndre Hopkins NFL FLAG Football   •   Ovarian CanceRx: New Innovative Clinical Research Effort Seeks to Accelerate the Development of New Treatments for Deadliest Gyn   •   In Memoriam: Pacific Islanders in Communication Mourns the Passing of Beloved Executive Director, Leanne Ferrer   •   Barron’s Names Edelman Financial Engines America’s Top Independent Registered Investment Advisor
Bookmark and Share

Mycovia Pharmaceuticals Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Oteseconazole for the Trea

DURHAM, N.C. , July 28 /Businesswire/ - Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for oteseconazole, an oral antifungal product for the treatment of recurrent vulvovaginal candidiasis (RVVC). Also known as chronic yeast infection, RVVC is a distinct condition from vulvovaginal candidiasis (VVC) and defined as three or more symptomatic acute episodes of yeast infection per year. RVVC affects nearly 138 million women worldwide each year and 6 million women in the U.S. alone. There are currently no FDA-approved treatments.

The FDA previously granted oteseconazole Priority Review, which is a designation reserved for potential drugs that, if approved, would mark significant improvements in the safety or effectiveness in the treatment of serious conditions. Under the Prescription Drug User Fee Act (PDUFA), the FDA set a six-month period with a target action date of January 27, 2022.

Mycovia’s NDA for oteseconazole is supported by positive results from three Phase 3 trials – two global VIOLET studies and one U.S.-focused ultraVIOLET study, including more than 870 patients at 232 sites across 11 countries. Both VIOLET studies met their primary and key secondary endpoints. Additionally, results from ultraVIOLET demonstrated oteseconazole’s effectiveness in treating the initial episode of VVC and reinforced its efficacy and safety profile in treating RVVC as compared to fluconazole, the current standard of care for VVC. Combined Phase 3 data showed that oteseconazole protected more than 90% of participants from having a recurrence for nearly a year.

“RVVC is a different condition from yeast infections, simply known as VVC, so it requires a different treatment,” said Patrick Jordan, CEO of Mycovia Pharmaceuticals and Partner at NovaQuest Capital Management, which formed Mycovia in 2018. “Research shows that fluconazole, the standard of care for VVC, is more than 90% effective in treating an initial episode of VVC1, but in studies of patients with RVVC, greater than 50% of women experience a recurrence following maintenance therapy discontinuation2.”

“We designed oteseconazole to address this need as a highly selective targeted oral therapy that demonstrates improved efficacy with fewer side effects than current treatment options, including fluconazole,” Jordan continued. “Supported by rigorous clinical trials evaluating the safety and efficacy of oteseconazole, we are eager for the FDA to review the application for our product, which has the potential to be the first FDA-approved therapy indicated for RVVC.”

Oteseconazole was granted Qualified Infectious Disease Product (QIDP) and Fast-Track designations by the FDA. With this timeline and pending full FDA review and approval, Mycovia is preparing for a U.S. launch of oteseconazole in early 2022.

About Mycovia Pharmaceuticals

Mycovia Pharmaceuticals is a late-stage emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies. Our lead product candidate, oteseconazole (VT-1161), is a novel, oral therapy for RVVC that is designed with the goal of having greater selectivity, fewer side effects and improved efficacy. While not yet approved by the FDA, oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations to support its potential to be the first FDA-approved treatment for RVVC. In 2019, Mycovia licensed oteseconazole to Jiangsu Hengrui Medicine Co., to develop and commercialize oteseconazole in China, including mainland China, Hong Kong, Macau and Taiwan, and Gedeon Richter Plc., a Hungary-based pharmaceutical company, to commercialize and manufacture oteseconazole in Europe, Russia, the Commonwealth of Independent States, Latin America and Australia. Mycovia also recognizes a tremendous potential for its oral fungal inhibitors and a growing need to treat a range of multi-drug resistant fungal pathogens. For more information, please visit www.mycovia.com.

About Oteseconazole

Oteseconazole (VT-1161) is a novel, investigational oral therapy for the treatment of recurrent vulvovaginal candidiasis (RVVC). Oteseconazole is designed with the goal of having greater selectivity, fewer side effects and improved efficacy as compared with currently available antifungal agents. Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations and, if approved, could be the first FDA-approved treatment for RVVC. Oteseconazole Phase 3 clinical trials were conducted in 11 countries. For more information, please visit https://www.mycovia.com/pipeline.

About Recurrent Vulvovaginal Candidiasis

RVVC is a debilitating, chronic infectious condition that affects 138 million women worldwide each year. RVVC, also known as chronic yeast infection, is a distinct condition from vulvovaginal candidiasis (VVC) and defined as three or more symptomatic acute episodes of yeast infection per year. Primary symptoms include vaginal itching, burning, irritation and inflammation. Some women may experience abnormal vaginal discharge and painful sexual intercourse or urination, causing variable but often severe discomfort and pain.

About NovaQuest Capital Management

Founded by a team of accomplished industry professionals who began working together in 2000, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a PRODUCT FINANCE™ investment solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate significantly higher than the industry average. Currently managing more than $2.2 billion in capital, NovaQuest is actively investing from the $1.2 billion Pharma Opportunities Fund V, evaluating global opportunities with financing needs that range from $30-100 million. For more information, please visit www.novaquest.com.

1Treatment of vaginal candidiasis with a single oral dose of fluconazole. Multicentre Study Group. Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):364-7. doi: 10.1007/BF01962338. PMID: 2842157.

2Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, Sperling M, Livengood C 3rd, Horowitz B, Von Thron J, Edwards L, Panzer H, Chu TC. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004 Aug 26;351(9):876-83. doi: 10.1056/NEJMoa033114. PMID: 15329425.


STORY TAGS: United States, North America, North Carolina, Women, Biotechnology, Pharmaceutical, Health, FDA, Infectious Diseases, Consumer, Clinical Trials, Funding, Product/Service,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News